{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T11:31:40Z","timestamp":1778931100895,"version":"3.51.4"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2019,10,16]],"date-time":"2019-10-16T00:00:00Z","timestamp":1571184000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,10,16]],"date-time":"2019-10-16T00:00:00Z","timestamp":1571184000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","award":["ITA-017"],"award-info":[{"award-number":["ITA-017"]}],"id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["IG16891"],"award-info":[{"award-number":["IG16891"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1007\/s00262-019-02411-y","type":"journal-article","created":{"date-parts":[[2019,10,16]],"date-time":"2019-10-16T19:40:29Z","timestamp":1571254829000},"page":"1791-1804","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Lenalidomide improves the therapeutic effect of an interferon-\u03b1-dendritic cell-based lymphoma vaccine"],"prefix":"10.1007","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2771-6813","authenticated-orcid":false,"given":"Caterina","family":"Lapenta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5214-9913","authenticated-orcid":false,"given":"Simona","family":"Donati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6610-350X","authenticated-orcid":false,"given":"Francesca","family":"Spadaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6998-4827","authenticated-orcid":false,"given":"Laura","family":"Lattanzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5522-2706","authenticated-orcid":false,"given":"Francesca","family":"Urbani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3870-8202","authenticated-orcid":false,"given":"Iole","family":"Macchia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7624-1025","authenticated-orcid":false,"given":"Paola","family":"Sestili","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Spada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8597-8459","authenticated-orcid":false,"given":"Maria Christina","family":"Cox","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3082-3169","authenticated-orcid":false,"given":"Filippo","family":"Belardelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7580-5589","authenticated-orcid":false,"given":"Stefano M.","family":"Santini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,10,16]]},"reference":[{"key":"2411_CR1","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1182\/blood-2015-11-624288","volume":"127","author":"BS Kahl","year":"2016","unstructured":"Kahl BS, Yang DT (2016) Follicular lymphoma: evolving therapeutic strategies. Blood 127:2055\u20132063. \nhttps:\/\/doi.org\/10.1182\/blood-2015-11-624288","journal-title":"Blood"},{"key":"2411_CR2","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1002\/ajh.24937","volume":"93","author":"A Freedman","year":"2018","unstructured":"Freedman A (2018) Follicular lymphoma: 2018 update on diagnosis and management. Am J Hematol 93:296\u2013305. \nhttps:\/\/doi.org\/10.1002\/ajh.24937","journal-title":"Am J Hematol"},{"key":"2411_CR3","doi-asserted-by":"publisher","first-page":"4555","DOI":"10.1200\/JCO.2008.21.3991","volume":"27","author":"M Federico","year":"2009","unstructured":"Federico M, Bellei M, Marcheselli L et al (2009) Follicular Lymphoma International Prognostic Index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol 27:4555\u20134562. \nhttps:\/\/doi.org\/10.1200\/JCO.2008.21.3991","journal-title":"J Clin Oncol"},{"key":"2411_CR4","doi-asserted-by":"publisher","first-page":"2575","DOI":"10.1200\/JCO.2015.65.7163","volume":"34","author":"C Sarkozy","year":"2016","unstructured":"Sarkozy C, Trneny M, Xerri L et al (2016) Risk factors and outcomes for patients with follicular lymphoma who had histologic transformation after response to first-line immunochemotherapy in the PRIMA trial. J Clin Oncol 34:2575\u20132582. \nhttps:\/\/doi.org\/10.1200\/JCO.2015.65.7163","journal-title":"J Clin Oncol"},{"key":"2411_CR5","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.it.2017.05.006","volume":"38","author":"AD Garg","year":"2017","unstructured":"Garg AD, Coulie PG, Van den Eynde BJ, Agostinis P (2017) Integrating next-generation dendritic cell vaccines into the current cancer immunotherapy landscape. Trends Immunol 38:577\u2013593. \nhttps:\/\/doi.org\/10.1016\/j.it.2017.05.006","journal-title":"Trends Immunol"},{"key":"2411_CR6","doi-asserted-by":"publisher","first-page":"e1386829","DOI":"10.1080\/2162402X.2017.1386829","volume":"6","author":"AD Garg","year":"2017","unstructured":"Garg AD, More S, Rufo N et al (2017) Trial watch: immunogenic cell death induction by anticancer chemotherapeutics. Oncoimmunology 6:e1386829. \nhttps:\/\/doi.org\/10.1080\/2162402X.2017.1386829","journal-title":"Oncoimmunology"},{"key":"2411_CR7","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.omtm.2017.03.004","volume":"5","author":"M Weinstock","year":"2017","unstructured":"Weinstock M, Rosenblatt J, Avigan D (2017) Dendritic cell therapies for hematologic malignancies. Mol Ther Methods Clin Dev 5:66\u201375. \nhttps:\/\/doi.org\/10.1016\/j.omtm.2017.03.004","journal-title":"Mol Ther Methods Clin Dev"},{"key":"2411_CR8","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1182\/blood-2008-06-165654","volume":"113","author":"M Di Nicola","year":"2009","unstructured":"Di Nicola M, Zappasodi R, Carlo-Stella C et al (2009) Vaccination with autologous tumor-loaded dendritic cells induces clinical and immunologic responses in indolent B-cell lymphoma patients with relapsed and measurable disease: a pilot study. Blood 113:18\u201327. \nhttps:\/\/doi.org\/10.1182\/blood-2008-06-165654","journal-title":"Blood"},{"key":"2411_CR9","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1182\/blood-2014-07-592162","volume":"125","author":"A Kolstad","year":"2015","unstructured":"Kolstad A, Kumari S, Walczak M et al (2015) Sequential intranodal immunotherapy induces antitumor immunity and correlated regression of disseminated follicular lymphoma. Blood 125:82\u201389. \nhttps:\/\/doi.org\/10.1182\/blood-2014-07-592162","journal-title":"Blood"},{"key":"2411_CR10","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1385\/1-59259-939-7:167","volume":"116","author":"SM Santini","year":"2005","unstructured":"Santini SM, Lapenta C, Belardelli F (2005) Type I interferons as regulators of the differentiation\/activation of human dendritic cells: methods for the evaluation of IFN-induced effects. Methods Mol Med 116:167\u2013181. \nhttps:\/\/doi.org\/10.1385\/1-59259-939-7:167","journal-title":"Methods Mol Med"},{"key":"2411_CR11","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1002\/eji.200535579","volume":"36","author":"C Lapenta","year":"2006","unstructured":"Lapenta C, Santini SM, Spada M et al (2006) IFN-alpha-conditioned dendritic cells are highly efficient in inducing cross-priming CD8+ T cells against exogenous viral antigens. Eur J Immunol 36:2046\u20132060. \nhttps:\/\/doi.org\/10.1002\/eji.200535579","journal-title":"Eur J Immunol"},{"key":"2411_CR12","doi-asserted-by":"publisher","first-page":"3022","DOI":"10.1182\/blood.V98.10.3022","volume":"98","author":"S Parlato","year":"2001","unstructured":"Parlato S, Santini SM, Lapenta C et al (2001) Expression of CCR-7, MIP-3beta, and Th-1 chemokines in type I IFN-induced monocyte-derived dendritic cells: importance for the rapid acquisition of potent migratory and functional activities. Blood 98:3022\u20133029","journal-title":"Blood"},{"key":"2411_CR13","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1084\/jem.20021924","volume":"198","author":"C Lapenta","year":"2003","unstructured":"Lapenta C, Santini SM, Logozzi M et al (2003) Potent immune response against HIV-1 and protection from virus challenge in hu-PBL-SCID mice immunized with inactivated virus-pulsed dendritic cells generated in the presence of IFN-alpha. J Exp Med 198:361\u2013367. \nhttps:\/\/doi.org\/10.1084\/jem.20021924","journal-title":"J Exp Med"},{"key":"2411_CR14","doi-asserted-by":"publisher","first-page":"e17364","DOI":"10.1371\/journal.pone.0017364","volume":"6","author":"SM Santini","year":"2011","unstructured":"Santini SM, Lapenta C, Donati S et al (2011) Interferon-\u03b1-conditioned human monocytes combine a Th1-orienting attitude with the induction of autologous Th17 responses: role of IL-23 and IL-12. PLoS One 6:e17364. \nhttps:\/\/doi.org\/10.1371\/journal.pone.0017364","journal-title":"PLoS One"},{"key":"2411_CR15","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1182\/blood-2011-06-363564","volume":"119","author":"F Spadaro","year":"2012","unstructured":"Spadaro F, Lapenta C, Donati S et al (2012) IFN-\u03b1 enhances cross-presentation in human dendritic cells by modulating antigen survival, endocytic routing, and processing. Blood 119:1407\u20131417. \nhttps:\/\/doi.org\/10.1182\/blood-2011-06-363564","journal-title":"Blood"},{"key":"2411_CR16","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.imbio.2010.10.003","volume":"216","author":"L Lattanzi","year":"2011","unstructured":"Lattanzi L, Rozera C, Marescotti D et al (2011) IFN-\u03b1 boosts epitope cross-presentation by dendritic cells via modulation of proteasome activity. Immunobiology 216:537\u2013547. \nhttps:\/\/doi.org\/10.1016\/j.imbio.2010.10.003","journal-title":"Immunobiology"},{"key":"2411_CR17","doi-asserted-by":"publisher","first-page":"795","DOI":"10.4049\/jimmunol.1600262","volume":"197","author":"C Lapenta","year":"2016","unstructured":"Lapenta C, Donati S, Spadaro F et al (2016) NK cell activation in the antitumor response induced by IFN-\u03b1 dendritic cells loaded with apoptotic cells from follicular lymphoma patients. J Immunol 197:795\u2013806. \nhttps:\/\/doi.org\/10.4049\/jimmunol.1600262","journal-title":"J Immunol"},{"key":"2411_CR18","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1093\/annonc\/mdv102","volume":"26","author":"TE Witzig","year":"2015","unstructured":"Witzig TE, Nowakowski GS, Habermann TM et al (2015) A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma. Ann Oncol 26:1667\u20131677. \nhttps:\/\/doi.org\/10.1093\/annonc\/mdv102","journal-title":"Ann Oncol"},{"key":"2411_CR19","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1002\/cncr.28405","volume":"120","author":"T Ahmadi","year":"2014","unstructured":"Ahmadi T, Chong EA, Gordon A et al (2014) Combined lenalidomide, low-dose dexamethasone, and rituximab achieves durable responses in rituximab-resistant indolent and mantle cell lymphomas. Cancer 120:222\u2013228. \nhttps:\/\/doi.org\/10.1002\/cncr.28405","journal-title":"Cancer"},{"key":"2411_CR20","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1158\/1078-0432.CCR-14-2221","volume":"21","author":"EA Chong","year":"2015","unstructured":"Chong EA, Ahmadi T, Aqui NA et al (2015) Combination of lenalidomide and rituximab overcomes rituximab resistance in patients with indolent B-cell and mantle cell lymphomas. Clin Cancer Res 21:1835\u20131842. \nhttps:\/\/doi.org\/10.1158\/1078-0432.CCR-14-2221","journal-title":"Clin Cancer Res"},{"key":"2411_CR21","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1097\/CJI.0000000000000097","volume":"38","author":"T-N Nguyen-Pham","year":"2015","unstructured":"Nguyen-Pham T-N, Jung S-H, Vo M-C et al (2015) Lenalidomide synergistically enhances the effect of dendritic cell vaccination in a model of murine multiple myeloma. J Immunother 38:330\u2013339. \nhttps:\/\/doi.org\/10.1097\/CJI.0000000000000097","journal-title":"J Immunother"},{"key":"2411_CR22","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.15917","author":"M-C Vo","year":"2017","unstructured":"Vo M-C, Nguyen-Pham T-N, Lee H-J et al (2017) Combination therapy with dendritic cells and lenalidomide is an effective approach to enhance antitumor immunity in a mouse colon cancer model. Oncotarget. \nhttps:\/\/doi.org\/10.18632\/oncotarget.15917","journal-title":"Oncotarget"},{"key":"2411_CR23","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.exphem.2016.11.004","volume":"46","author":"M-C Vo","year":"2017","unstructured":"Vo M-C, Anh-NguyenThi T, Lee H-J et al (2017) Lenalidomide enhances the function of dendritic cells generated from patients with multiple myeloma. Exp Hematol 46:48\u201355. \nhttps:\/\/doi.org\/10.1016\/j.exphem.2016.11.004","journal-title":"Exp Hematol"},{"key":"2411_CR24","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/leu.2011.179","volume":"26","author":"G Epron","year":"2012","unstructured":"Epron G, Ame-Thomas P, Le Priol J et al (2012) Monocytes and T cells cooperate to favor normal and follicular lymphoma B-cell growth: role of IL-15 and CD40L signaling. Leukemia 26:139\u2013148. \nhttps:\/\/doi.org\/10.1038\/leu.2011.179","journal-title":"Leukemia"},{"key":"2411_CR25","doi-asserted-by":"publisher","first-page":"280","DOI":"10.3389\/fimmu.2012.00280","volume":"3","author":"F Mourcin","year":"2012","unstructured":"Mourcin F, Pangault C, Amin-Ali R et al (2012) Stromal cell contribution to human follicular lymphoma pathogenesis. Front Immunol 3:280. \nhttps:\/\/doi.org\/10.3389\/fimmu.2012.00280","journal-title":"Front Immunol"},{"key":"2411_CR26","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.semcancer.2013.08.001","volume":"24","author":"P Am\u00e9-Thomas","year":"2014","unstructured":"Am\u00e9-Thomas P, Tarte K (2014) The yin and the yang of follicular lymphoma cell niches: role of microenvironment heterogeneity and plasticity. Semin Cancer Biol 24:23\u201332. \nhttps:\/\/doi.org\/10.1016\/j.semcancer.2013.08.001","journal-title":"Semin Cancer Biol"},{"key":"2411_CR27","doi-asserted-by":"publisher","first-page":"e1356964","DOI":"10.1080\/2162402X.2017.1356964","volume":"6","author":"B Montico","year":"2017","unstructured":"Montico B, Lapenta C, Ravo M et al (2017) Exploiting a new strategy to induce immunogenic cell death to improve dendritic cell-based vaccines for lymphoma immunotherapy. Oncoimmunology 6:e1356964. \nhttps:\/\/doi.org\/10.1080\/2162402X.2017.1356964","journal-title":"Oncoimmunology"},{"key":"2411_CR28","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/726239","author":"I Macchia","year":"2013","unstructured":"Macchia I, Urbani F, Proietti E (2013) Immune monitoring in cancer vaccine clinical trials: critical issues of functional flow cytometry-based assays. Biomed Res Int. \nhttps:\/\/doi.org\/10.1155\/2013\/726239","journal-title":"Biomed Res Int"},{"key":"2411_CR29","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-540-71029-5_14","author":"SM Santini","year":"2009","unstructured":"Santini SM, Lapenta C, Santodonato L et al (2009) IFN-alpha in the generation of dendritic cells for cancer immunotherapy. Handb Exp Pharmacol. \nhttps:\/\/doi.org\/10.1007\/978-3-540-71029-5_14","journal-title":"Handb Exp Pharmacol"},{"key":"2411_CR30","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1007\/s00262-008-0620-4","volume":"58","author":"C Galustian","year":"2009","unstructured":"Galustian C, Meyer B, Labarthe M-C et al (2009) The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunol Immunother 58:1033\u20131045. \nhttps:\/\/doi.org\/10.1007\/s00262-008-0620-4","journal-title":"Cancer Immunol Immunother"},{"key":"2411_CR31","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1056\/NEJMoa1805104","volume":"379","author":"F Morschhauser","year":"2018","unstructured":"Morschhauser F, Fowler NH, Feugier P et al (2018) Rituximab plus lenalidomide in advanced untreated follicular lymphoma. N Engl J Med 379:934\u2013947. \nhttps:\/\/doi.org\/10.1056\/NEJMoa1805104","journal-title":"N Engl J Med"},{"key":"2411_CR32","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1111\/ejh.13065","volume":"101","author":"M Palma","year":"2018","unstructured":"Palma M, Hansson L, Mulder TA et al (2018) Lenalidomide as immune adjuvant to a dendritic cell vaccine in chronic lymphocytic leukemia patients. Eur J Haematol 101:68\u201377. \nhttps:\/\/doi.org\/10.1111\/ejh.13065","journal-title":"Eur J Haematol"},{"key":"2411_CR33","doi-asserted-by":"publisher","first-page":"3999","DOI":"10.1002\/cncr.25983","volume":"117","author":"B-N Lee","year":"2011","unstructured":"Lee B-N, Gao H, Cohen EN et al (2011) Treatment with lenalidomide modulates T-cell immunophenotype and cytokine production in patients with chronic lymphocytic leukemia. Cancer 117:3999\u20134008. \nhttps:\/\/doi.org\/10.1002\/cncr.25983","journal-title":"Cancer"},{"key":"2411_CR34","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/leu.2008.247","volume":"23","author":"MC Minnema","year":"2009","unstructured":"Minnema MC, van der Veer MS, Aarts T et al (2009) Lenalidomide alone or in combination with dexamethasone is highly effective in patients with relapsed multiple myeloma following allogeneic stem cell transplantation and increases the frequency of CD4\u2009+\u2009Foxp3\u2009+\u2009T cells. Leukemia 23:605\u2013607. \nhttps:\/\/doi.org\/10.1038\/leu.2008.247","journal-title":"Leukemia"},{"key":"2411_CR35","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1182\/blood-2011-04-348292","volume":"118","author":"E Kneppers","year":"2011","unstructured":"Kneppers E, van der Holt B, Kersten M-J et al (2011) Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial. Blood 118:2413\u20132419. \nhttps:\/\/doi.org\/10.1182\/blood-2011-04-348292","journal-title":"Blood"},{"key":"2411_CR36","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/bmt.2009.155","volume":"45","author":"M Lioznov","year":"2010","unstructured":"Lioznov M, El-Cheikh J, Hoffmann F et al (2010) Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44+) and T (HLA-DR+) cells. Bone Marrow Transplant 45:349\u2013353. \nhttps:\/\/doi.org\/10.1038\/bmt.2009.155","journal-title":"Bone Marrow Transplant"},{"key":"2411_CR37","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1111\/cei.12343","volume":"177","author":"A Busch","year":"2014","unstructured":"Busch A, Zeh D, Janzen V et al (2014) Treatment with lenalidomide induces immunoactivating and counter-regulatory immunosuppressive changes in myeloma patients. Clin Exp Immunol 177:439\u2013453. \nhttps:\/\/doi.org\/10.1111\/cei.12343","journal-title":"Clin Exp Immunol"},{"key":"2411_CR38","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.3109\/10428194.2011.652106","volume":"53","author":"KR Muthu Raja","year":"2012","unstructured":"Muthu Raja KR, Kovarova L, Hajek R (2012) Induction by lenalidomide and dexamethasone combination increases regulatory cells of patients with previously untreated multiple myeloma. Leuk Lymphoma 53:1406\u20131408. \nhttps:\/\/doi.org\/10.3109\/10428194.2011.652106","journal-title":"Leuk Lymphoma"},{"key":"2411_CR39","doi-asserted-by":"publisher","first-page":"193","DOI":"10.3324\/haematol.11702","volume":"93","author":"A Tzankov","year":"2008","unstructured":"Tzankov A, Meier C, Hirschmann P et al (2008) Correlation of high numbers of intratumoral FOXP3\u2009+\u2009regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin\u2019s lymphoma. Haematologica 93:193\u2013200. \nhttps:\/\/doi.org\/10.3324\/haematol.11702","journal-title":"Haematologica"},{"key":"2411_CR40","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2010.28.15_suppl.8085","author":"N Aqui","year":"2010","unstructured":"Aqui N, Leinbach L, Chong EA et al (2010) Changes in regulatory T-cells in responding and non-responding patients with indolent B-cell or mantle cell lymphomas during treatment with lenalidomide, dexamethasone, and rituximab. J Clin Oncol. \nhttps:\/\/doi.org\/10.1200\/jco.2010.28.15_suppl.8085","journal-title":"J Clin Oncol"},{"key":"2411_CR41","doi-asserted-by":"publisher","first-page":"4713","DOI":"10.1182\/blood-2009-04-217687","volume":"114","author":"AG Ramsay","year":"2009","unstructured":"Ramsay AG, Clear AJ, Kelly G et al (2009) Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy. Blood 114:4713\u20134720. \nhttps:\/\/doi.org\/10.1182\/blood-2009-04-217687","journal-title":"Blood"},{"key":"2411_CR42","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.mvr.2008.08.003","volume":"77","author":"L Lu","year":"2009","unstructured":"Lu L, Payvandi F, Wu L et al (2009) The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions. Microvasc Res 77:78\u201386. \nhttps:\/\/doi.org\/10.1016\/j.mvr.2008.08.003","journal-title":"Microvasc Res"},{"key":"2411_CR43","doi-asserted-by":"publisher","first-page":"7254","DOI":"10.1158\/0008-5472.CAN-13-0750","volume":"73","author":"K Song","year":"2013","unstructured":"Song K, Herzog BH, Sheng M et al (2013) Lenalidomide inhibits lymphangiogenesis in preclinical models of mantle cell lymphoma. Cancer Res 73:7254\u20137264. \nhttps:\/\/doi.org\/10.1158\/0008-5472.CAN-13-0750","journal-title":"Cancer Res"},{"key":"2411_CR44","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1593\/neo.121962","volume":"15","author":"D Ribatti","year":"2013","unstructured":"Ribatti D, Nico B, Ranieri G et al (2013) The role of angiogenesis in human non-Hodgkin lymphomas. Neoplasia 15:231\u2013238","journal-title":"Neoplasia"},{"key":"2411_CR45","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.it.2007.07.006","volume":"28","author":"S Sozzani","year":"2007","unstructured":"Sozzani S, Rusnati M, Riboldi E et al (2007) Dendritic cell-endothelial cell cross-talk in angiogenesis. Trends Immunol 28:385\u2013392. \nhttps:\/\/doi.org\/10.1016\/j.it.2007.07.006","journal-title":"Trends Immunol"},{"key":"2411_CR46","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s12967-015-0473-5","volume":"13","author":"C Rozera","year":"2015","unstructured":"Rozera C, Cappellini GA, D\u2019Agostino G et al (2015) Intratumoral injection of IFN-alpha dendritic cells after dacarbazine activates anti-tumor immunity: results from a phase I trial in advanced melanoma. J Transl Med 13:139. \nhttps:\/\/doi.org\/10.1186\/s12967-015-0473-5","journal-title":"J Transl Med"},{"key":"2411_CR47","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-0709","author":"MC Cox","year":"2019","unstructured":"Cox MC, Castiello L, Mattei M et al (2019) Clinical and antitumor immune responses in relapsed\/refractory follicular lymphoma patients after intranodal injections of IFN\u03b1-dendritic cells and rituximab. Clin Cancer Res. \nhttps:\/\/doi.org\/10.1158\/1078-0432.CCR-19-0709","journal-title":"Clin Cancer Res"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-019-02411-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00262-019-02411-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-019-02411-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,14]],"date-time":"2020-10-14T23:36:47Z","timestamp":1602718607000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00262-019-02411-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,16]]},"references-count":47,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["2411"],"URL":"https:\/\/doi.org\/10.1007\/s00262-019-02411-y","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,16]]},"assertion":[{"value":"15 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Stefano M. Santini received research funding from Celgene. All other authors declare that they have no conflict of interest. Celgene had no role in study design, data collection, data interpretation, writing of the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All experiments utilizing PBMC from healthy donors were conducted in accordance with the ethical standards of the Ethics Committee of Istituto Superiore di Sanit\u00e0 and the Declaration of Helsinki. Institutional Review Board approval was not required for this kind of study. Buffy coat supply for our studies was approved by Azienda Ospedaliera Policlinico Umberto I on 24\/02\/2014 (aut.6802). All experiments utilizing blood samples from FL patients were conducted in accordance with the declaration of Helsinki. Study and procedures were approved by the Ethics Committee of Azienda Ospedaliera Sant\u2019Andrea (aut.169\/2011). All experiments on mice were executed in compliance with the Istituto Superiore di Sanit\u00e0 Service for Animal Welfare guidelines and after approval from the Italian Ministry of Health (aut. 296\/2015-PR). Mice were housed according to Legislative Decree 26\/2014 guideline.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"PBMC were freshly isolated from peripheral blood samples of anonymous volunteer healthy donors at the Transfusion Center of of Policlinico Umberto I\u2014University \u201cLa Sapienza\u201d, Rome. Written informed consent was obtained from all blood donors to the use of their blood for research and scientific purposes. Blood samples from FL patients were anonymously provided by the Hematology Unit at the Azienda Ospedaliera Sant\u2019Andrea Rome, Italy. Written informed consent was obtained from FL patients for the use of blood and lymph node specimens in IFN-DC-based vaccine researches.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"NOD\/SCID (NOD.CB17-Prkdcscid\/NCrHsd) female mice were purchased from Envigo (Italy), used at 3\u20134\u2004weeks of age.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Animal source"}},{"value":"Karpas-422 FL cell line was purchased from the cell bank Interlab Cell Line Collection (ICLC). Human K562 erythroleukemic cell line was purchased from the European Collection of Authenticated Cell Culture (ECACC). Both cell lines were authenticated by the suppliers by short tandem repeat (STR) profiling. The cell lines were initially grown and cryopreserved into multiple aliquots. All the experiments were performed with cells at low passage numbers (\u2264\u00a010).","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Cell line authentication"}}]}}